ChemomAb specializes in the development of proprietary monoclonal antibodies for the treatment of immune-mediated and fibrotic disorders.
Business Model:
Revenue: $0
Employees: 11-50
Address: Kiryat Atidim,
City: Tel Aviv
State: tel aviv district
Zip: .6158002
Country: IL
ChemomAb specializes in the development of proprietary monoclonal antibodies for the treatment of immune-mediated and fibrotic disorders.
Contact Phone:
Contact Email:
Listed Exchange:
NASDAQ
IPO Date:
3/16/2021
Ticker Symbol:
CMMB
Opened: -/share
EBITDA | - |
Total Cash | - |
Total Debt | - |
Total Revenue | - |
Total Profit (Gross) | - |
PE Ratio | - |
Announced Date | Company | Transaction | Money Raised |
---|
Announced Date | Transaction | Number of Investors | Money Raised | Lead Investors | 12/2017 | Series B | 4 | $10M |
Peter Thiel OrbiMed OrbiMed Peter Thiel SBI Japan-Israel Innovation Fund Activate Venture Partners Peter Thiel OrbiMed OrbiMed Peter Thiel |
12/2019 | Series C | 3 | $20M |
OrbiMed Presight Capital Thiel Capital OrbiMed Thiel Capital OrbiMed Presight Capital Thiel Capital OrbiMed Thiel Capital |
3/2021 | Post-IPO Equity | 5 | $45.5M |
Apeiron Investment Group Cormorant Asset Management OrbiMed Peter Thiel Presight Capital Presight Capital Apeiron Investment Group Cormorant Asset Management Peter Thiel OrbiMed Apeiron Investment Group Cormorant Asset Management Presight Capital |
9/2016 | Series A | 1 | $5M |
OrbiMed OrbiMed |
---|
Announced Date | Name | Price |
---|---|---|
3/2021 | Anchiano Therapeutics |
|
Revenue: 0 - 100000 Employees: Industry: Software |
Details
|
|
Revenue: 0 - 100000 Employees: 51 - 500 Industry: Education |
Details
|
|
Revenue: 0 - 100000 Employees: 1 - 10 Industry: Blockchain |
Details
|
|
Revenue: 0 - 100000 Employees: 11 - 50 Industry: Industrial |
Details
|
|
Revenue: 0 - 100000 Employees: 1 - 10 Industry: Advertising |
Details
|